Novavax disclosed that the U.K. government had agreed to purchase 60 million doses of NVX-CoV2373, its COVID-19 vaccine candidate.
Novavax did not disclose the financial terms of the agreement. As part of the deal, the U.K. will collaborate with the company on its phase three clinical trial, which is expected to begin this quarter.
The potential vaccine, named NVX-CoV2373, will be tested on around 9,000 adults between ages 18 and 85, the company said.
In a released statement said by Novavax CEO Stanley Erck, “We are honored to partner with the UK government to deliver a vaccine that could provide vital protection in the fight against the global health crisis.”
“Our Phase 3 clinical trial in the UK will be a critical component to assess the efficacy of NVX-CoV2373, which in a Phase 1 trial has already demonstrated to be generally well-tolerated and to elicit robust antibody responses,” he added.
The company expects the 15,000-patient study will be fully enrolled by the end of November. Novavax is also planning to run a phase 3 study of NVX-CoV2373 in the U.S. and Mexico. That trial is scheduled to start by the end of November.